Snappy newsletters. Simple Facebook sharing. Spirited comments. Sweet features are waiting… GET THEM NOW!

NEWS ABOUT: GlaxoSmithKline

Stories 1 - 20 |  Next >>

Switch to grid view »

HPV Vaccine Price to Plummet for Poor Countries

Merck, GlaxoSmthKline will offer them for less than $5

(Newser) - Two of the world's biggest drug companies have agreed to slash the price of their HPV vaccines—which currently cost around $130 a dose in the US—down to less than $5 in some developing nations, the companies announced today. Thanks to a deal negotiated by the nonprofit GAVI... More »

New Fountain of Youth: Red Wine Pills

GlaxoSmithKline developing drugs based on resveratrol

(Newser) - You've no doubt heard that drinking red wine is good for your health. But scientists and Big Pharma alike are getting excited about putting the health-boosting essence of red wine in pill form. GlaxoSmithKline is working on a slew of new pills that do just that, the Daily Mail... More »

Swine Flu Shot May Have Caused Kids' Narcolepsy

795 European recipients of GlaxoSmithKline drug report illness

(Newser) - Children across Europe have been developing narcolepsy at increased rates since 2009—and experts fear the crisis may be linked to a GlaxoSmithKline swine flu vaccine. The incurable sleep disorder has surged in Sweden, Finland, Norway, France, and Britain, experts say, and it can take a devastating toll: Reuters recounts... More »

Critics Fume as Big Pharma Funds Drug Studies

'The evidence base has been perverted,' expert says

(Newser) - Think studies of new drugs in the New England Journal of Medicine are unassailable? Experts are beginning to wonder, because pharmaceutical companies pay academics to conduct many of those studies—and the approval of high-profile drugs like Vioxx, Avandia, and Celebrex has led to thousands of deaths, the Washington Post... More »

Glaxo Buying Human Genome Sciences

After big drug failure in 2011, Human Genome failed to find higher bid

(Newser) - British pharma giant GlaxoSmithKline is poised to announce a $2.8 billion takeover of Human Genome Sciences, perhaps as early as today, reports Reuters . US-based Human Genome, which uses the human DNA sequence to develop drugs, balked at Glaxo's original $2.6 billion offer and said it would go... More »

Glaxo Paid Dr. Drew to Talk Up Drug for Depression

He got $200K over 2 months in 1999

(Newser) - GlaxoSmithKline this week agreed to pay $3 billion to settle a fraud case alleging that it took too many liberties in how it promoted its drugs, and Forbes notes a high-profile name mentioned in court documents: Dr. Drew Pinsky. Prosecutors said Glaxo paid Dr. Drew $275,000 over two months... More »

GlaxoSmithKline Settles Fraud Case for Record $3B

It's the largest penalty ever paid by a health care company in US

(Newser) - GlaxoSmithKline is about to set a new record: It's paying $3 billion in what government officials say is the largest health care fraud settlement in US history, the AP reports. The company will plead guilty to charges related to three drugs, the Justice Department says: Prosecutors say GSK promoted... More »

Disgraced Doctors Land at Big Pharma

Hundreds of pitchmen found to have blemished records

(Newser) - Pharmaceutical companies say they hire highly respected doctors as their white-coat sales force, peddling their drugs to other physicians. But a Pro Publica investigation has discovered that hundreds of these pitchmen have been accused of professional misconduct, been disciplined by state boards, or lacked credentials. Medical board records in the... More »

FDA Restricts Diabetes Drug Over Heart Risk

But regulators stop short of an outright ban on Avandia

(Newser) - The FDA today put severe restrictions on Avandia, GlaxoSmithKline’s embattled diabetes drug, but stopped short of banning it outright. The once-popular drug will now only be available only as a last resort to type 2 diabetes patients who can’t control their glucose levels with any other medication, the... More »

FDA Panel: Keep Avandia on Market

But it may get warning label on heart risks

(AP) - A majority of federal health experts has voted to keep the controversial diabetes pill Avandia on the market despite evidence that it increases the risk of heart attack. A panel of Food and Drug Administration advisers voted 20-12 against withdrawing GlaxoSmithKline's once-blockbuster drug. The agency is not required to follow... More »

Avandia Woes Mount Ahead of FDA Hearing

Agency flags flawed study, may ban diabetes drug

(Newser) - As the FDA prepares to consider whether to ban Avandia, agency scientists have discovered another problem with the diabetes drug: flaws that disqualify a clinical study sponsored by its maker. The trial, organized by GlaxoSmithKline, sought to evaluate the relative heart risks of Avandia and two other diabetes drugs, but... More »

Diabetes Drug Linked to Heart Woes Again; FDA Weighs Ban

Avandia less safe than alternatives; FDA weighs action

(Newser) - The mountain of evidence against diabetes drug Avandia grew a bit bigger today, with two major studies linking the medication to heart disease and stroke, the LA Times reports. An FDA panel will meet next month to discuss recalling the drug, which has been on the agency's radar at least... More »

Drug for Enlarged Prostate Cuts Cancer Risk, Too

Tumors stop growing or even shrink in study

(Newser) - A drug designed to shrink enlarged prostates may also be able to reduce the risk that at-risk men will develop prostate cancer, according to a new study. The drug dutasteride, sold under the brand name Avodart, was found to reduce the risk of cancer by roughly 25%. Researchers report seeing... More »

Feds Further Link Avandia to Heart Risk

FDA, Senate reports lambaste GlaxoSmithKline, want to yank drug

(Newser) - Some 800 people every month suffer heart attacks or heart failure because of the diabetes medication Avandia, according to government reports obtained by the New York Times . Under fire since 2007, the GlaxoSmithKline drug was linked to 304 deaths in the final quarter of last year and hundreds of thousands... More »

Glaxo Offers Free Access to Malaria Research

Company makes vast database public to help science find a cure

(Newser) - GlaxoSmithKline has opened up its database of compounds with the potential to cure malaria to any scientists who wants to take up the challenge. The move—unheard of in the pharmaceutical industry—comes after company scientists spent a year screening all 2 million compounds in the company's library for those... More »

Antidepressants Don't Work for 70% of Patients

Little better than placebos in all but the most severe cases

(Newser) - Antidepressants are little better than a placebo for all but the most severe cases of depression, according to a new analysis of recent studies. “For patients with very severe depression, the medication did have a potent effect,” the study’s lead author tells WebMD . But the effects “... More »

Anti-Smoking Chantix, Zyban Pose Suicide Risk: FDA

Smokers with mental illnesses should avoid them, agency says

(Newser) - The Food and Drug Administration is warning smokers about serious mental-illness risks of two smoking-cessation drugs, as reported suicides among their users increase. Chantix and Zyban must now carry the agency’s strongest warning label, the New York Times reports. The FDA isn’t trying to scare patients, an official... More »

Swiss Pharma Won't Donate Swine Flu Vaccine to Poor

Novartis defies WHO calls to give free doses to poor

(Newser) - Swiss pharma giant Novartis is defying the World Health Organization by refusing to donate swine flu vaccines to the world's poor, despite the designation of H1N1 as the first pandemic in 40 years, reports the Financial Times. Last week the WHO's director general called on drug companies to show "... More »

Pharma Pushes Dow Down 83

Sandisk gains after earnings beating expectations

(Newser) - Stocks were mixed today as pharmaceuticals declined but tech saw gains, the Wall Street Journal reports. GlaxoSmithKline reported a 13% drop in first-quarter earnings; GSK, Merck and Pfizer shares dropped. Yahoo and Sandisk were up despite posting quarterly losses. The Dow fell 82.99 to close at 7,886.57.... More »

Glaxo to Cut Drug Prices in Developing World

No. 2 pharma firm will open 'patent pool' to outside scientists

(Newser) - GlaxoSmithKline’s new boss has proposed a radical rethinking of big pharma in developing countries: He plans to cut prices, offer portions of profits to hospitals, and loosen his firm’s grip on patents that keep prices up, the Guardian reports. “I think it's absolutely the kind of thing... More »

Stories 1 - 20 |  Next >>
NEWS FROM OUR PARTNERS
Other Sites We Like:   24/7 Wall St.   |   BuzzFeed   |   Cracked   |   Timelines   |   POPSUGAR Tech   |   Business Insider   |   HuffPost Entertainment   |   NewsOne